沃森生物
(300142)
| 流通市值：208.28亿 | | | 总市值：211.11亿 |
| 流通股本：15.78亿 | | | 总股本：15.99亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 834,215,184.81 | 443,848,309.81 | 2,418,234,933.46 | 1,718,807,933.37 |
| 营业总成本 | 803,971,819.98 | 406,874,077.19 | 2,107,110,191.82 | 1,488,300,078.09 |
| 其他经营收益 | | | | |
| 营业利润 | 73,430,044.1 | 131,054,857.36 | 187,949,310.11 | 140,353,629.75 |
| 利润总额 | 69,206,201.16 | 128,938,125.59 | 166,112,393.23 | 136,278,616.67 |
| 净利润 | 45,939,173.56 | 114,413,869.69 | 125,157,091.43 | 103,512,939.99 |
| 每股收益 | | | | |
| 其他综合收益 | 32,392.13 | - | 213,017,400 | 106,250,000 |
| 综合收益总额 | 45,971,565.69 | 114,413,869.69 | 338,174,491.43 | 209,762,939.99 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,045,768,646.31 | 4,329,045,639.34 | 4,546,332,984.65 | 5,912,282,709.35 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,454,111,647.68 | 6,799,239,065.42 | 7,524,256,256.61 | 7,339,582,207.34 |
| 资产总计 | 10,499,880,293.99 | 11,128,284,704.76 | 12,070,589,241.26 | 13,251,864,916.69 |
| 流动负债: | | | | |
| 流动负债合计 | 1,950,492,218.99 | 2,001,918,172.99 | 1,937,123,384.7 | 1,678,427,087.04 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,218,278,457.38 | 1,312,896,044.42 | 597,073,860.22 | 630,232,463.27 |
| 负债合计 | 3,168,770,676.37 | 3,314,814,217.41 | 2,534,197,244.92 | 2,308,659,550.31 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,980,865,668.84 | 7,408,481,999.52 | 8,620,990,550.95 | 9,683,242,545.41 |
| 股东权益合计 | 7,331,109,617.62 | 7,813,470,487.35 | 9,536,391,996.34 | 10,943,205,366.38 |
| 负债和股东权益合计 | 10,499,880,293.99 | 11,128,284,704.76 | 12,070,589,241.26 | 13,251,864,916.69 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,179,520,631.04 | 468,908,289.54 | 2,788,916,431.97 | 1,850,051,940.04 |
| 经营活动现金流出小计 | 1,005,603,344.05 | 489,147,342.58 | 2,297,990,265.81 | 1,770,359,850.28 |
| 经营活动产生的现金流量净额 | 173,917,286.99 | -20,239,053.04 | 490,926,166.16 | 79,692,089.76 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 321,749,249.1 | 6,661,283.13 | 192,895,570.81 | 161,922,690.01 |
| 投资活动现金流出小计 | 366,592,647.48 | 144,889,103.18 | 509,544,939.65 | 357,253,150.1 |
| 投资活动产生的现金流量净额 | -44,843,398.38 | -138,227,820.05 | -316,649,368.84 | -195,330,460.09 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,197,094,887.96 | 977,260,053.13 | 305,800,605.75 | 2,440,000 |
| 筹资活动现金流出小计 | 1,908,224,046.3 | 1,200,265,927 | 2,889,984,280.2 | 1,969,865,412.91 |
| 筹资活动产生的现金流量净额 | -711,129,158.34 | -223,005,873.87 | -2,584,183,674.45 | -1,967,425,412.91 |
| 汇率变动对现金及现金等价物的影响 | -3,215,886.35 | -1,147,114.85 | -951,793.34 | 908,358.77 |
| 现金及现金等价物净增加额 | -585,271,156.08 | -382,619,861.81 | -2,410,858,670.47 | -2,082,155,424.47 |
| 期末现金及现金等价物余额 | 762,972,989.46 | 965,624,283.73 | 1,348,244,145.54 | 1,676,947,391.54 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -585,271,156.08 | - | -2,410,858,670.47 | - |